Irish and colleagues first demonstrated that SYK phosphorylation and BCR-mediated signaling occurred more rapidly in FL tumor B-cells compared to non-tumor B-cells, providing a therapeutic rationale for SYK inhibition in this disease [44]. This evidence concerns the gene SYK and neoplasm.